slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 6,271-6,300
Pages 296
Rows per page 30
Slide type
6,271-6,300 of 8,880
10
Uses an analogy to travel booking platforms (Amadeus/Sabre and Booking.com/Expedia) to explain the business model.Freightos | Investor Presentation Deck | 35 slides · Freightos
Pitch deck Investor relations Beat · Solution1 hit
11
The slide uses a value-chain style flow to show the integration of different market participants.Freightos | Investor Presentation Deck | 35 slides · Freightos
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a 'before-after' logic to explain the transition from 177Lu to 225Ac.Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
08
The slide illustrates a sequential therapeutic approach: THIO treatment followed by CPI therapy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
07
The slide outlines the technical workflow from sample collection to diagnostic output.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
04
The slide uses a combination of molecular diagrams and bulleted benefits to explain the LNC technology.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
05
The slide uses a two-part framework: Targeting (left) and Delivery (right).Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
08
Uses a before-after-bridge style logic to frame the solution.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
17
Uses a combination of an additive equation for the value prop and a chevron-based timeline for the life cycle management.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
06
The central hub is 'Accelerate Product Development', surrounded by four strategic pillars, each with a corresponding icon.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide highlights the scalability and versatility of the platform from research to clinical manufacturing.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
18
The slide contrasts a traditional, lengthy development process with the accelerated VLx-enabled approach.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
19
The slide uses a timeline-based comparison to highlight time savings (6+ months vs 1-2 months).MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
07
The slide uses a medical illustration of the liver to highlight the target organ.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
The diagram shows a biological pathway from steatosis to steatohepatitis to fibrosis, highlighting the role of GPR119 activation in modulating cellular responses.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
10
The slide shows two heatmaps (17 inflammation genes, 22 stellate cell activation genes) and a biological pathway diagram.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
Includes specific study references and definitions for abbreviations like GPR119, MASH, and GLP-1.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The slide uses a diagram to map the drug's mechanism of action to specific biological effects in the liver, pancreas, and immune system.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of the hormone.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
06
The slide uses a biological mechanism-of-action illustration to show how the drug components interact with specific cellular stressors.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a combination of a biological mechanism diagram and a pharmacokinetic line chart to prove efficacy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
09
The chart demonstrates that PrimeC aligns the peak concentrations of two different drugs, which is the core value proposition of their formulation technology.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a series of blue blocks to represent different research pillars/methodologies within the PARADIGM trial.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a list of four key pillars of the company's methodology.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
10
Uses a 'cite_precedent' framework to validate the strategy by comparing it to the established success of Osimertinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide presents two distinct scientific data sets: an IC50 dot plot for in vitro activity and a bar chart for in vivo tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
Includes a formula for Selectivity index and a legend for various compound mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and contrast current standards of care with the proposed solution's benefits.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
Includes specific pharmacological data points for NVL-520 vs competitors like Crizotinib, Entrectinib, Lorlatinib, Taletrectinib, and Repotrectinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
39
The slide uses a 'ribbon' style callout box on the right for key product attributes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit